BioLife Solutions, Inc. (BLFS) 10-Year Financial Performance & Capital Metrics

BLFS • • Industrial / General

HealthcareMedical InstrumentsBiopharma & Life Science ToolsBioprocessing & Cell Therapy Tools

AboutBioLife Solutions, Inc. develops, manufactures, and supplies bioproduction tools and services for the cell and gene therapy industry in the United States, Canada, Europe, the Middle East, Africa, and internationally. The company's products are used in the basic and applied research, and commercial manufacturing of biologic-based therapies. It offers proprietary biopreservation media products, including HypoThermosol FRS and CryoStor that are formulated to mitigate preservation-induced, delayed-onset cell damage and death; and the ThawSTAR line that includes automated vial and cryobag thawing products that control the heat and timing of the thawing process of biologic materials. The company also provides evo shipping containers that are cloud-connected passive storage and transport containers for temperature-sensitive biologics and pharmaceuticals; liquid nitrogen laboratory freezers, cryogenic equipment, and accessories; and biological and pharmaceutical storage services. It markets and sells its products directly, as well as through third party distributors. BioLife Solutions, Inc. was incorporated in 1987 and is headquartered in Bothell, Washington.Show more

Revenue $82M -42.6%
EBITDA $2M +102.6%
Net Income -$20M +69.6%
EPS (Diluted) -0.44 +71.1%
Gross Margin 65.25% +100.0%
EBITDA Margin 1.86% +104.6%
Operating Margin -8.67% +82.5%
Net Margin -24.54% +47.1%
ROE -5.88% +68.9%
ROIC -1.7% +88.3%
Debt/Equity 0.09 -13.7%
Interest Coverage -9.92 +74.6%

Technical Analysis

Key Insights

Based on financial data analysis

✓Strengths

✓Company is almost debt free
✓Strong 5Y sales CAGR of 24.6%

✗Weaknesses

✗Low asset turnover indicates capital-intensive operations

Price & Volume

Loading chart...

Growth Metrics

Revenue CAGR

10Y29.52%

5Y24.62%

3Y-11.62%

TTM-14.06%

Profit (Net Income) CAGR

10Y-

5Y-

3Y-

TTM93.03%

EPS CAGR

10Y-

5Y-

3Y-

TTM93.1%

ROCE

10Y Avg-12.82%

5Y Avg-6.66%

3Y Avg-7.16%

Latest-1.93%

Peer Comparison

Bioprocessing & Cell Therapy Tools

Name	Market Cap	Current Price	P/E Ratio	Revenue Growth 1Y	Net Margin	ROE	FCF Yield	Debt/Equity
BLFSBioLife Solutions, Inc.	1.18B	24.47	-55.61	-42.59%	-4.33%	-0.91%	0.44%	0.09
RGENRepligen Corporation	9.1B	161.69	-351.50	0.33%	0.25%	0.08%	1.57%	0.35

Profit & Loss

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Sales/Revenue+	6.45M	8.23M	11.02M	19.74M	27.37M	48.09M	119.16M	76.24M	143.27M	82.25M
Revenue Growth %	0.04%	0.28%	0.34%	0.79%	0.39%	0.76%	1.48%	-0.36%	0.88%	-0.43%
Cost of Goods Sold+	2.63M	3.45M	4.28M	6.22M	8.86M	20.65M	81.41M	107.94M	96.52M	28.58M
COGS % of Revenue	0.41%	0.42%	0.39%	0.31%	0.32%	0.43%	0.68%	1.42%	0.67%	0.35%
Gross Profit+	3.81M	4.78M	6.75M	13.53M	18.51M	27.44M	37.75M	53.82M	46.75M	53.67M
Gross Margin %	0.59%	0.58%	0.61%	0.69%	0.68%	0.57%	0.32%	0.71%	0.33%	0.65%
Gross Profit Growth %	0.26%	0.25%	0.41%	1%	0.37%	0.48%	0.38%	0.43%	-0.13%	0.15%
Operating Expenses+	8.83M	9.63M	7.8M	9.86M	18.17M	30.77M	68.11M	93.73M	117.58M	60.8M
OpEx % of Revenue	1.37%	1.17%	0.71%	0.5%	0.66%	0.64%	0.57%	1.23%	0.82%	0.74%
Selling, General & Admin	7.45M	7.6M	6.61M	8.56M	14.05M	21.02M	48.09M	69.24M	80.31M	50.15M
SG&A % of Revenue	1.16%	0.92%	0.6%	0.43%	0.51%	0.44%	0.4%	0.91%	0.56%	0.61%
Research & Development	1.38M	2.03M	1.19M	1.3M	4.12M	6.72M	11.82M	14.8M	18.8M	7.91M
R&D % of Revenue	0.21%	0.25%	0.11%	0.07%	0.15%	0.14%	0.1%	0.19%	0.13%	0.1%
Other Operating Expenses	0	0	0	0	0	3.03M	8.2M	9.7M	18.47M	2.74M
Operating Income+	-5.02M	-4.85M	-1.06M	3.66M	-781K	-3.33M	-35.16M	-5.92M	-70.83M	-7.13M
Operating Margin %	-0.78%	-0.59%	-0.1%	0.19%	-0.03%	-0.07%	-0.3%	-0.08%	-0.49%	-0.09%
Operating Income Growth %	-0.6%	0.03%	0.78%	4.47%	-1.21%	-3.27%	-9.55%	0.83%	-10.96%	0.9%
EBITDA+	-4.67M	-4.48M	-717K	4M	1.53M	1.74M	-22.3M	14.04M	-58.53M	1.53M
EBITDA Margin %	-0.72%	-0.54%	-0.07%	0.2%	0.06%	0.04%	-0.19%	0.18%	-0.41%	0.02%
EBITDA Growth %	-0.62%	0.04%	0.84%	6.58%	-0.62%	0.14%	-13.84%	1.63%	-5.17%	1.03%
D&A (Non-Cash Add-back)	343.22K	368.1K	339K	338K	2.31M	5.07M	12.87M	19.96M	12.29M	8.66M
EBIT	-5.02M	-7.72M	-2.13M	-25M	770K	-3.59M	-29.52M	-144.14M	-57.53M	-7.13M
Net Interest Income+	21.75K	-315.97K	-454K	276K	501K	40K	-485K	-687K	-1.81M	-719K
Interest Income	21.75K	2.42K	1K	281K	506K	58K	0	0	0	0
Interest Expense	0	318.39K	455K	5K	5K	18K	485K	687K	1.81M	719K
Other Income/Expense	21.75K	-3.19M	-1.46M	-28.67M	-2.98M	4.98M	6.13M	1.07M	4.97M	-4.3M
Pretax Income+	-5M	-8.04M	-2.52M	3.27M	9.52M	-1.28M	-29.03M	-4.85M	-66.26M	-11.43M
Pretax Margin %	-0.77%	-0.98%	-0.23%	0.17%	0.35%	-0.03%	-0.24%	-0.06%	-0.46%	-0.14%
Income Tax+	0	1.62M	0	396K	-1.54M	-3.26M	-20.12M	-5.24M	169K	-38K
Effective Tax Rate %	0.84%	0.85%	1%	1%	-0.17%	-2.08%	0.31%	28.84%	1%	1.77%
Net Income+	-4.21M	-6.88M	-2.52M	3.27M	-1.66M	2.67M	-8.91M	-139.81M	-66.43M	-20.18M
Net Margin %	-0.65%	-0.84%	-0.23%	0.17%	-0.06%	0.06%	-0.07%	-1.83%	-0.46%	-0.25%
Net Income Growth %	-0.31%	-0.63%	0.63%	2.3%	-1.51%	2.61%	-4.34%	-14.69%	0.52%	0.7%
Net Income (Continuing)	-5M	-8.04M	-2.52M	-25M	0	1.98M	-8.91M	388K	-66.43M	-11.39M
Discontinued Operations	0	0	0	0	0	0	0	-140.19M	0	-8.8M
Minority Interest	1.35M	0	0	0	0	0	0	0	0	0
EPS (Diluted)+	-0.35	-0.54	-0.21	-1.56	-0.09	-0.06	-0.23	-3.29	-1.52	-0.44
EPS Growth %	-0.13%	-0.54%	0.61%	-6.43%	0.95%	0.3%	-2.85%	-13.3%	0.54%	0.71%
EPS (Basic)	-0.35	-0.54	-0.21	-1.56	-0.09	0.07	-0.23	-3.29	-1.52	-0.44
Diluted Shares Outstanding	12.18M	12.64M	13.26M	16.26M	19.46M	27.31M	38.5M	42.48M	43.72M	46.07M
Basic Shares Outstanding	12.18M	12.64M	13.26M	16.26M	19.46M	27.31M	38.5M	42.48M	43.72M	46.07M
Dividend Payout Ratio	-	-	-	-	-	-	-	-	-	-

Balance Sheet

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Total Current Assets+	6.97M	4.63M	9.93M	37.56M	24.18M	114.71M	125.86M	138.45M	120.6M	148.76M
Cash & Short-Term Investments	3.82M	1.41M	6.66M	30.66M	6.45M	90.46M	69.87M	62.7M	44.18M	104.58M
Cash Only	3.82M	1.41M	6.66M	30.66M	6.45M	90.46M	69.87M	19.44M	27.9M	95.39M
Short-Term Investments	0	0	0	0	0	0	0	43.26M	16.29M	9.2M
Accounts Receivable	929.29K	1.19M	1.02M	3.04M	5.34M	8.01M	23.22M	33.94M	18.66M	9.17M
Days Sales Outstanding	52.6	52.96	33.81	56.3	71.28	60.77	71.12	162.47	47.53	40.68
Inventory	1.83M	1.76M	1.85M	3.51M	11.12M	11.6M	28.34M	34.9M	43.46M	29.01M
Days Inventory Outstanding	254.16	186.1	157.66	206.01	458.25	205.11	127.09	118.03	164.33	370.49
Other Current Assets	0	0	0	0	-85K	0	-229K	6.91M	14.31M	6M
Total Non-Current Assets+	5.4M	3.3M	2.21M	7.9M	68.83M	120.12M	426.75M	311.78M	292.11M	250.73M
Property, Plant & Equipment	1.45M	1.19M	1.11M	1.32M	6.61M	19.81M	36.8M	39.2M	32.62M	16.76M
Fixed Asset Turnover	4.46x	6.93x	9.97x	14.97x	4.14x	2.43x	3.24x	1.94x	4.39x	4.91x
Goodwill	0	0	0	0	33.64M	58.45M	224.74M	224.74M	224.74M	212.3M
Intangible Assets	3.91M	0	0	0	21.98M	31.05M	152.15M	32.09M	21.15M	9.56M
Long-Term Investments	0	2.08M	1.07M	6.55M	2.5M	5.87M	4.37M	6.4M	13.33M	5.62M
Other Non-Current Assets	36.17K	36.62K	35.84K	36K	3.92M	4.71M	9.81M	9.35M	-20.88M	6.48M
Total Assets+	12.37M	7.93M	12.14M	45.47M	93.01M	234.83M	552.6M	450.23M	412.71M	399.49M
Asset Turnover	0.52x	1.04x	0.91x	0.43x	0.29x	0.20x	0.22x	0.17x	0.35x	0.21x
Asset Growth %	-0.23%	-0.36%	0.53%	2.74%	1.05%	1.52%	1.35%	-0.19%	-0.08%	-0.03%
Total Current Liabilities+	1.73M	1.13M	1.51M	1.94M	7.78M	15.57M	42.7M	44.58M	42.18M	32.73M
Accounts Payable	1.03M	710.72K	691K	720K	3.12M	3.67M	14.95M	15.37M	6.94M	3.57M
Days Payables Outstanding	142.6	75.24	58.98	42.27	128.52	64.92	67.01	51.97	26.24	45.63
Short-Term Debt	0	0	0	0	13K	614K	862K	1.81M	6.29M	10.94M
Deferred Revenue (Current)	0	0	130K	130K	324K	931K	814K	548K	661K	103K
Other Current Liabilities	130.22K	344.47K	130K	159K	1.96M	6.34M	21.52M	20.71M	23.21M	5.23M
Current Ratio	4.04x	4.08x	6.56x	19.37x	3.11x	7.37x	2.95x	3.11x	2.86x	4.54x
Quick Ratio	2.98x	2.53x	5.34x	17.56x	1.68x	6.62x	2.28x	2.32x	1.83x	3.66x
Cash Conversion Cycle	164.15	163.82	132.49	220.04	401	200.96	131.2	228.54	185.62	365.55
Total Non-Current Liabilities+	784.46K	3.63M	538K	380K	2.21M	14.01M	31.88M	41.46M	32.87M	17.84M
Long-Term Debt	0	2.84M	0	0	0	655K	6.35M	23.79M	17.56M	5M
Capital Lease Obligations	0	0	0	0	550K	8.77M	16.76M	15.09M	8.7M	12.72M
Deferred Tax Liabilities	0	0	0	0	0	0	5.49M	250K	114K	124K
Other Non-Current Liabilities	784.46K	685.45K	538K	28.9M	0	4.51M	4.94M	2.33M	6.5M	0
Total Liabilities	2.51M	4.76M	2.05M	2.32M	9.98M	29.58M	71.85M	86.04M	75.05M	50.58M
Total Debt+	0	2.84M	0	0	1.35M	11.15M	26.88M	43.71M	33.83M	30.17M
Net Debt	-3.82M	1.44M	-6.66M	-30.66M	-5.09M	-79.3M	-42.99M	24.27M	5.93M	-65.21M
Debt / Equity	-	0.90x	-	-	0.02x	0.05x	0.06x	0.12x	0.10x	0.09x
Debt / EBITDA	-	-	-	-	0.89x	6.42x	-	3.11x	-	19.70x
Net Debt / EBITDA	-	-	-	-7.66x	-3.33x	-45.68x	-	1.73x	-	-42.57x
Interest Coverage	-	-15.24x	-2.32x	732.40x	-156.20x	-185.11x	-72.49x	-8.62x	-39.09x	-9.92x
Total Equity+	9.86M	3.17M	10.09M	43.15M	83.03M	205.25M	480.75M	364.19M	337.66M	348.91M
Equity Growth %	-0.39%	-0.68%	2.19%	3.28%	0.92%	1.47%	1.34%	-0.24%	-0.07%	0.03%
Book Value per Share	0.81	0.25	0.76	2.65	4.27	7.52	12.49	8.57	7.72	7.57
Total Shareholders' Equity	8.51M	3.17M	10.09M	43.15M	83.03M	205.25M	480.75M	364.19M	337.66M	348.91M
Common Stock	12.45K	12.86K	14.02K	19K	21K	33K	42K	43K	45K	47K
Retained Earnings	-64.33M	-71.2M	-73.96M	-71.03M	-100.05M	-97.39M	-105.02M	-246.91M	-313.34M	-335.1M
Treasury Stock	0	0	0	0	0	0	0	0	0	0
Accumulated OCI	-451	-1.67M	-2.01M	-2.33M	0	0	-282K	-679K	-345K	24K
Minority Interest	1.35M	0	0	0	0	0	0	0	0	0

Cash Flow

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Cash from Operations+	-4.97M	-4.33M	605K	2.35M	1.21M	6.51M	-4.84M	-8.49M	-12.5M	8.43M
Operating CF Margin %	-0.77%	-0.53%	0.05%	0.12%	0.04%	0.14%	-0.04%	-0.11%	-0.09%	0.1%
Operating CF Growth %	-0.57%	0.13%	1.14%	2.88%	-0.48%	4.37%	-1.74%	-0.76%	-0.47%	1.67%
Net Income	-5M	-8.04M	-2.52M	3.27M	-1.66M	2.67M	-7.63M	-139.81M	-66.43M	-20.18M
Depreciation & Amortization	343.22K	368.1K	338.68K	338K	1.8M	5.07M	12.87M	16.47M	12.29M	5.49M
Stock-Based Compensation	511.46K	776.99K	1.27M	1.52M	3.04M	5.98M	13.96M	25.33M	31.67M	30.92M
Deferred Taxes	90.13K	2.79M	1M	672K	-1.54M	-3.3M	-20.13M	-5.24M	-62K	-64K
Other Non-Cash Items	-127K	313.13K	203.54K	-127K	4.04M	-2.12M	-364K	109.65M	8.56M	-7.96M
Working Capital Changes	-796.29K	-532.76K	302.93K	-3.32M	-4.47M	-1.78M	-3.53M	-14.9M	1.47M	227K
Change in Receivables	-27.67K	-264.36K	172.33K	-2.02M	-290K	-1.79M	-10.13M	-10.75M	15.35M	-2.9M
Change in Inventory	-869.41K	-290.84K	-88.96K	-1.66M	-3.78M	-629K	114K	-6.56M	-8.55M	781K
Change in Payables	194.39K	233.48K	20.58K	-11K	768K	-171K	2.02M	414K	-8.43M	26K
Cash from Investing+	4.24M	393K	-144K	-6.5M	-27.02M	-23.73M	-12.64M	-58.12M	17.84M	58.3M
Capital Expenditures	-1.42M	-1.26M	-143.77K	-500K	-675K	-4.63M	-8.38M	-10.38M	-6.38M	-3.23M
CapEx % of Revenue	0.22%	0.15%	0.01%	0.03%	0.02%	0.1%	0.07%	0.14%	0.04%	0.04%
Acquisitions	-	-	-	-	-	-	-	-	-	-
Investments	-	-	-	-	-	-	-	-	-	-
Other Investing	-1.37B	208	-233	-6M	-1.66M	-3.17M	-5.82M	-3.54M	-4.86M	-2.37M
Cash from Financing+	368.75K	3.17M	4.8M	28.15M	1.6M	102.08M	-2.78M	16.32M	10.59M	-6.78M
Debt Issued (Net)	-	-	-	-	-	-	-	-	-	-
Equity Issued (Net)	-	-	-	-	-	-	-	-	-	-
Dividends Paid	0	0	-106.25K	-436K	0	0	0	0	0	0
Share Repurchases	-	-	-	-	-	-	-	-	-	-
Other Financing	368.75K	166.77K	3.93M	12.83M	1.6M	973K	-1.16M	-1.71M	845K	-377K
Net Change in Cash	-	-	-	-	-	-	-	-	-	-
Free Cash Flow+	-6.39M	-5.58M	461.23K	1.85M	538K	1.88M	-13.22M	-18.87M	-18.88M	5.2M
FCF Margin %	-0.99%	-0.68%	0.04%	0.09%	0.02%	0.04%	-0.11%	-0.25%	-0.13%	0.06%
FCF Growth %	-0.7%	0.13%	1.08%	3.01%	-0.71%	2.5%	-8.02%	-0.43%	-0%	1.28%
FCF per Share	-0.52	-0.44	0.03	0.11	0.03	0.07	-0.34	-0.44	-0.43	0.11
FCF Conversion (FCF/Net Income)	1.18x	0.63x	-0.24x	0.72x	-0.73x	2.44x	0.54x	0.06x	0.19x	-0.42x
Interest Paid	0	0	0	0	0	0	0	0	0	0
Taxes Paid	0	0	0	0	0	0	0	0	0	0

Key Ratios

Metric	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024
Return on Equity (ROE)	-32.5%	-105.56%	-37.94%	12.27%	-2.63%	1.85%	-2.6%	-33.09%	-18.93%	-5.88%
Return on Invested Capital (ROIC)	-61.86%	-68.4%	-19.72%	34.5%	-1.3%	-2.45%	-9.36%	-1.08%	-14.51%	-1.7%
Gross Margin	59.15%	58.09%	61.2%	68.51%	67.64%	57.07%	31.68%	70.6%	32.63%	65.25%
Net Margin	-65.34%	-83.57%	-22.82%	16.54%	-6.05%	5.55%	-7.48%	-183.38%	-46.36%	-24.54%
Debt / Equity	-	0.90x	-	-	0.02x	0.05x	0.06x	0.12x	0.10x	0.09x
Interest Coverage	-	-15.24x	-2.32x	732.40x	-156.20x	-185.11x	-72.49x	-8.62x	-39.09x	-9.92x
FCF Conversion	1.18x	0.63x	-0.24x	0.72x	-0.73x	2.44x	0.54x	0.06x	0.19x	-0.42x
Revenue Growth	4.17%	27.57%	33.97%	79.11%	38.64%	75.69%	147.79%	-36.02%	87.92%	-42.59%

Revenue by Segment

	2019	2020	2021	2022	2023	2024
Product	-	-	-	-	117.69M	76.03M
Product Growth	-	-	-	-	-	-35.40%
Rental Revenue	-	-	14.8M	4.63M	8.03M	6.07M
Rental Revenue Growth	-	-	-	-68.68%	73.14%	-24.41%
Service	-	-	-	-	17.55M	160K
Service Growth	-	-	-	-	-	-99.09%
Service Revenue	-	4.55M	108K	210K	-	-
Service Revenue Growth	-	-	-97.63%	94.44%	-	-
Biopreservation Media	23.36M	-	-	-	-	-
Biopreservation Media Growth	-	-	-	-	-	-
Freezers and Accessories	2.14M	-	-	-	-	-
Freezers and Accessories Growth	-	-	-	-	-	-
Automated Thawing Products	1.18M	-	-	-	-	-
Automated Thawing Products Growth	-	-	-	-	-	-
Evo Shippers	692K	-	-	-	-	-
Evo Shippers Growth	-	-	-	-	-	-

Frequently Asked Questions

Growth & Financials

BioLife Solutions, Inc. (BLFS) reported $74.0M in revenue for fiscal year 2024. This represents a 2583% increase from $2.8M in 2011.

BioLife Solutions, Inc. (BLFS) saw revenue decline by 42.6% over the past year.

BioLife Solutions, Inc. (BLFS) reported a net loss of $3.2M for fiscal year 2024.

Dividend & Returns

BioLife Solutions, Inc. (BLFS) has a return on equity (ROE) of -5.9%. Negative ROE indicates the company is unprofitable.

BioLife Solutions, Inc. (BLFS) generated $10.6M in free cash flow for fiscal year 2024. Positive FCF indicates the company can fund dividends, buybacks, or reinvestment.

US Stock Screener

...

BioLife Solutions, Inc. (BLFS) 10-Year Financial Performance & Capital Metrics

BLFS • • Industrial / General

HealthcareMedical InstrumentsBiopharma & Life Science ToolsBioprocessing & Cell Therapy Tools

Revenue $82M -42.6%
EBITDA $2M +102.6%
Net Income -$20M +69.6%
EPS (Diluted) -0.44 +71.1%
Gross Margin 65.25% +100.0%
EBITDA Margin 1.86% +104.6%
Operating Margin -8.67% +82.5%
Net Margin -24.54% +47.1%
ROE -5.88% +68.9%
ROIC -1.7% +88.3%
Debt/Equity 0.09 -13.7%
Interest Coverage -9.92 +74.6%

Technical Analysis

Key Insights

Based on financial data analysis

✓Strengths

✓Company is almost debt free
✓Strong 5Y sales CAGR of 24.6%

✗Weaknesses

✗Low asset turnover indicates capital-intensive operations

Price & Volume

Loading chart...

Growth Metrics

Revenue CAGR

10Y29.52%

5Y24.62%

3Y-11.62%

TTM-14.06%

Profit (Net Income) CAGR

10Y-

5Y-

3Y-

TTM93.03%

EPS CAGR

10Y-

5Y-

3Y-

TTM93.1%

ROCE

10Y Avg-12.82%

5Y Avg-6.66%

3Y Avg-7.16%

Latest-1.93%

Peer Comparison

Bioprocessing & Cell Therapy Tools

Name	Market Cap	Current Price	P/E Ratio	Revenue Growth 1Y	Net Margin	ROE	FCF Yield	Debt/Equity
BLFSBioLife Solutions, Inc.	1.18B	24.47	-55.61	-42.59%	-4.33%	-0.91%	0.44%	0.09
RGENRepligen Corporation	9.1B	161.69	-351.50	0.33%	0.25%	0.08%	1.57%	0.35

Profit & Loss

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Sales/Revenue+	6.45M	8.23M	11.02M	19.74M	27.37M	48.09M	119.16M	76.24M	143.27M	82.25M
Revenue Growth %	0.04%	0.28%	0.34%	0.79%	0.39%	0.76%	1.48%	-0.36%	0.88%	-0.43%
Cost of Goods Sold+	2.63M	3.45M	4.28M	6.22M	8.86M	20.65M	81.41M	107.94M	96.52M	28.58M
COGS % of Revenue	0.41%	0.42%	0.39%	0.31%	0.32%	0.43%	0.68%	1.42%	0.67%	0.35%
Gross Profit+	3.81M	4.78M	6.75M	13.53M	18.51M	27.44M	37.75M	53.82M	46.75M	53.67M
Gross Margin %	0.59%	0.58%	0.61%	0.69%	0.68%	0.57%	0.32%	0.71%	0.33%	0.65%
Gross Profit Growth %	0.26%	0.25%	0.41%	1%	0.37%	0.48%	0.38%	0.43%	-0.13%	0.15%
Operating Expenses+	8.83M	9.63M	7.8M	9.86M	18.17M	30.77M	68.11M	93.73M	117.58M	60.8M
OpEx % of Revenue	1.37%	1.17%	0.71%	0.5%	0.66%	0.64%	0.57%	1.23%	0.82%	0.74%
Selling, General & Admin	7.45M	7.6M	6.61M	8.56M	14.05M	21.02M	48.09M	69.24M	80.31M	50.15M
SG&A % of Revenue	1.16%	0.92%	0.6%	0.43%	0.51%	0.44%	0.4%	0.91%	0.56%	0.61%
Research & Development	1.38M	2.03M	1.19M	1.3M	4.12M	6.72M	11.82M	14.8M	18.8M	7.91M
R&D % of Revenue	0.21%	0.25%	0.11%	0.07%	0.15%	0.14%	0.1%	0.19%	0.13%	0.1%
Other Operating Expenses	0	0	0	0	0	3.03M	8.2M	9.7M	18.47M	2.74M
Operating Income+	-5.02M	-4.85M	-1.06M	3.66M	-781K	-3.33M	-35.16M	-5.92M	-70.83M	-7.13M
Operating Margin %	-0.78%	-0.59%	-0.1%	0.19%	-0.03%	-0.07%	-0.3%	-0.08%	-0.49%	-0.09%
Operating Income Growth %	-0.6%	0.03%	0.78%	4.47%	-1.21%	-3.27%	-9.55%	0.83%	-10.96%	0.9%
EBITDA+	-4.67M	-4.48M	-717K	4M	1.53M	1.74M	-22.3M	14.04M	-58.53M	1.53M
EBITDA Margin %	-0.72%	-0.54%	-0.07%	0.2%	0.06%	0.04%	-0.19%	0.18%	-0.41%	0.02%
EBITDA Growth %	-0.62%	0.04%	0.84%	6.58%	-0.62%	0.14%	-13.84%	1.63%	-5.17%	1.03%
D&A (Non-Cash Add-back)	343.22K	368.1K	339K	338K	2.31M	5.07M	12.87M	19.96M	12.29M	8.66M
EBIT	-5.02M	-7.72M	-2.13M	-25M	770K	-3.59M	-29.52M	-144.14M	-57.53M	-7.13M
Net Interest Income+	21.75K	-315.97K	-454K	276K	501K	40K	-485K	-687K	-1.81M	-719K
Interest Income	21.75K	2.42K	1K	281K	506K	58K	0	0	0	0
Interest Expense	0	318.39K	455K	5K	5K	18K	485K	687K	1.81M	719K
Other Income/Expense	21.75K	-3.19M	-1.46M	-28.67M	-2.98M	4.98M	6.13M	1.07M	4.97M	-4.3M
Pretax Income+	-5M	-8.04M	-2.52M	3.27M	9.52M	-1.28M	-29.03M	-4.85M	-66.26M	-11.43M
Pretax Margin %	-0.77%	-0.98%	-0.23%	0.17%	0.35%	-0.03%	-0.24%	-0.06%	-0.46%	-0.14%
Income Tax+	0	1.62M	0	396K	-1.54M	-3.26M	-20.12M	-5.24M	169K	-38K
Effective Tax Rate %	0.84%	0.85%	1%	1%	-0.17%	-2.08%	0.31%	28.84%	1%	1.77%
Net Income+	-4.21M	-6.88M	-2.52M	3.27M	-1.66M	2.67M	-8.91M	-139.81M	-66.43M	-20.18M
Net Margin %	-0.65%	-0.84%	-0.23%	0.17%	-0.06%	0.06%	-0.07%	-1.83%	-0.46%	-0.25%
Net Income Growth %	-0.31%	-0.63%	0.63%	2.3%	-1.51%	2.61%	-4.34%	-14.69%	0.52%	0.7%
Net Income (Continuing)	-5M	-8.04M	-2.52M	-25M	0	1.98M	-8.91M	388K	-66.43M	-11.39M
Discontinued Operations	0	0	0	0	0	0	0	-140.19M	0	-8.8M
Minority Interest	1.35M	0	0	0	0	0	0	0	0	0
EPS (Diluted)+	-0.35	-0.54	-0.21	-1.56	-0.09	-0.06	-0.23	-3.29	-1.52	-0.44
EPS Growth %	-0.13%	-0.54%	0.61%	-6.43%	0.95%	0.3%	-2.85%	-13.3%	0.54%	0.71%
EPS (Basic)	-0.35	-0.54	-0.21	-1.56	-0.09	0.07	-0.23	-3.29	-1.52	-0.44
Diluted Shares Outstanding	12.18M	12.64M	13.26M	16.26M	19.46M	27.31M	38.5M	42.48M	43.72M	46.07M
Basic Shares Outstanding	12.18M	12.64M	13.26M	16.26M	19.46M	27.31M	38.5M	42.48M	43.72M	46.07M
Dividend Payout Ratio	-	-	-	-	-	-	-	-	-	-

Balance Sheet

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Total Current Assets+	6.97M	4.63M	9.93M	37.56M	24.18M	114.71M	125.86M	138.45M	120.6M	148.76M
Cash & Short-Term Investments	3.82M	1.41M	6.66M	30.66M	6.45M	90.46M	69.87M	62.7M	44.18M	104.58M
Cash Only	3.82M	1.41M	6.66M	30.66M	6.45M	90.46M	69.87M	19.44M	27.9M	95.39M
Short-Term Investments	0	0	0	0	0	0	0	43.26M	16.29M	9.2M
Accounts Receivable	929.29K	1.19M	1.02M	3.04M	5.34M	8.01M	23.22M	33.94M	18.66M	9.17M
Days Sales Outstanding	52.6	52.96	33.81	56.3	71.28	60.77	71.12	162.47	47.53	40.68
Inventory	1.83M	1.76M	1.85M	3.51M	11.12M	11.6M	28.34M	34.9M	43.46M	29.01M
Days Inventory Outstanding	254.16	186.1	157.66	206.01	458.25	205.11	127.09	118.03	164.33	370.49
Other Current Assets	0	0	0	0	-85K	0	-229K	6.91M	14.31M	6M
Total Non-Current Assets+	5.4M	3.3M	2.21M	7.9M	68.83M	120.12M	426.75M	311.78M	292.11M	250.73M
Property, Plant & Equipment	1.45M	1.19M	1.11M	1.32M	6.61M	19.81M	36.8M	39.2M	32.62M	16.76M
Fixed Asset Turnover	4.46x	6.93x	9.97x	14.97x	4.14x	2.43x	3.24x	1.94x	4.39x	4.91x
Goodwill	0	0	0	0	33.64M	58.45M	224.74M	224.74M	224.74M	212.3M
Intangible Assets	3.91M	0	0	0	21.98M	31.05M	152.15M	32.09M	21.15M	9.56M
Long-Term Investments	0	2.08M	1.07M	6.55M	2.5M	5.87M	4.37M	6.4M	13.33M	5.62M
Other Non-Current Assets	36.17K	36.62K	35.84K	36K	3.92M	4.71M	9.81M	9.35M	-20.88M	6.48M
Total Assets+	12.37M	7.93M	12.14M	45.47M	93.01M	234.83M	552.6M	450.23M	412.71M	399.49M
Asset Turnover	0.52x	1.04x	0.91x	0.43x	0.29x	0.20x	0.22x	0.17x	0.35x	0.21x
Asset Growth %	-0.23%	-0.36%	0.53%	2.74%	1.05%	1.52%	1.35%	-0.19%	-0.08%	-0.03%
Total Current Liabilities+	1.73M	1.13M	1.51M	1.94M	7.78M	15.57M	42.7M	44.58M	42.18M	32.73M
Accounts Payable	1.03M	710.72K	691K	720K	3.12M	3.67M	14.95M	15.37M	6.94M	3.57M
Days Payables Outstanding	142.6	75.24	58.98	42.27	128.52	64.92	67.01	51.97	26.24	45.63
Short-Term Debt	0	0	0	0	13K	614K	862K	1.81M	6.29M	10.94M
Deferred Revenue (Current)	0	0	130K	130K	324K	931K	814K	548K	661K	103K
Other Current Liabilities	130.22K	344.47K	130K	159K	1.96M	6.34M	21.52M	20.71M	23.21M	5.23M
Current Ratio	4.04x	4.08x	6.56x	19.37x	3.11x	7.37x	2.95x	3.11x	2.86x	4.54x
Quick Ratio	2.98x	2.53x	5.34x	17.56x	1.68x	6.62x	2.28x	2.32x	1.83x	3.66x
Cash Conversion Cycle	164.15	163.82	132.49	220.04	401	200.96	131.2	228.54	185.62	365.55
Total Non-Current Liabilities+	784.46K	3.63M	538K	380K	2.21M	14.01M	31.88M	41.46M	32.87M	17.84M
Long-Term Debt	0	2.84M	0	0	0	655K	6.35M	23.79M	17.56M	5M
Capital Lease Obligations	0	0	0	0	550K	8.77M	16.76M	15.09M	8.7M	12.72M
Deferred Tax Liabilities	0	0	0	0	0	0	5.49M	250K	114K	124K
Other Non-Current Liabilities	784.46K	685.45K	538K	28.9M	0	4.51M	4.94M	2.33M	6.5M	0
Total Liabilities	2.51M	4.76M	2.05M	2.32M	9.98M	29.58M	71.85M	86.04M	75.05M	50.58M
Total Debt+	0	2.84M	0	0	1.35M	11.15M	26.88M	43.71M	33.83M	30.17M
Net Debt	-3.82M	1.44M	-6.66M	-30.66M	-5.09M	-79.3M	-42.99M	24.27M	5.93M	-65.21M
Debt / Equity	-	0.90x	-	-	0.02x	0.05x	0.06x	0.12x	0.10x	0.09x
Debt / EBITDA	-	-	-	-	0.89x	6.42x	-	3.11x	-	19.70x
Net Debt / EBITDA	-	-	-	-7.66x	-3.33x	-45.68x	-	1.73x	-	-42.57x
Interest Coverage	-	-15.24x	-2.32x	732.40x	-156.20x	-185.11x	-72.49x	-8.62x	-39.09x	-9.92x
Total Equity+	9.86M	3.17M	10.09M	43.15M	83.03M	205.25M	480.75M	364.19M	337.66M	348.91M
Equity Growth %	-0.39%	-0.68%	2.19%	3.28%	0.92%	1.47%	1.34%	-0.24%	-0.07%	0.03%
Book Value per Share	0.81	0.25	0.76	2.65	4.27	7.52	12.49	8.57	7.72	7.57
Total Shareholders' Equity	8.51M	3.17M	10.09M	43.15M	83.03M	205.25M	480.75M	364.19M	337.66M	348.91M
Common Stock	12.45K	12.86K	14.02K	19K	21K	33K	42K	43K	45K	47K
Retained Earnings	-64.33M	-71.2M	-73.96M	-71.03M	-100.05M	-97.39M	-105.02M	-246.91M	-313.34M	-335.1M
Treasury Stock	0	0	0	0	0	0	0	0	0	0
Accumulated OCI	-451	-1.67M	-2.01M	-2.33M	0	0	-282K	-679K	-345K	24K
Minority Interest	1.35M	0	0	0	0	0	0	0	0	0

Cash Flow

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Cash from Operations+	-4.97M	-4.33M	605K	2.35M	1.21M	6.51M	-4.84M	-8.49M	-12.5M	8.43M
Operating CF Margin %	-0.77%	-0.53%	0.05%	0.12%	0.04%	0.14%	-0.04%	-0.11%	-0.09%	0.1%
Operating CF Growth %	-0.57%	0.13%	1.14%	2.88%	-0.48%	4.37%	-1.74%	-0.76%	-0.47%	1.67%
Net Income	-5M	-8.04M	-2.52M	3.27M	-1.66M	2.67M	-7.63M	-139.81M	-66.43M	-20.18M
Depreciation & Amortization	343.22K	368.1K	338.68K	338K	1.8M	5.07M	12.87M	16.47M	12.29M	5.49M
Stock-Based Compensation	511.46K	776.99K	1.27M	1.52M	3.04M	5.98M	13.96M	25.33M	31.67M	30.92M
Deferred Taxes	90.13K	2.79M	1M	672K	-1.54M	-3.3M	-20.13M	-5.24M	-62K	-64K
Other Non-Cash Items	-127K	313.13K	203.54K	-127K	4.04M	-2.12M	-364K	109.65M	8.56M	-7.96M
Working Capital Changes	-796.29K	-532.76K	302.93K	-3.32M	-4.47M	-1.78M	-3.53M	-14.9M	1.47M	227K
Change in Receivables	-27.67K	-264.36K	172.33K	-2.02M	-290K	-1.79M	-10.13M	-10.75M	15.35M	-2.9M
Change in Inventory	-869.41K	-290.84K	-88.96K	-1.66M	-3.78M	-629K	114K	-6.56M	-8.55M	781K
Change in Payables	194.39K	233.48K	20.58K	-11K	768K	-171K	2.02M	414K	-8.43M	26K
Cash from Investing+	4.24M	393K	-144K	-6.5M	-27.02M	-23.73M	-12.64M	-58.12M	17.84M	58.3M
Capital Expenditures	-1.42M	-1.26M	-143.77K	-500K	-675K	-4.63M	-8.38M	-10.38M	-6.38M	-3.23M
CapEx % of Revenue	0.22%	0.15%	0.01%	0.03%	0.02%	0.1%	0.07%	0.14%	0.04%	0.04%
Acquisitions	-	-	-	-	-	-	-	-	-	-
Investments	-	-	-	-	-	-	-	-	-	-
Other Investing	-1.37B	208	-233	-6M	-1.66M	-3.17M	-5.82M	-3.54M	-4.86M	-2.37M
Cash from Financing+	368.75K	3.17M	4.8M	28.15M	1.6M	102.08M	-2.78M	16.32M	10.59M	-6.78M
Debt Issued (Net)	-	-	-	-	-	-	-	-	-	-
Equity Issued (Net)	-	-	-	-	-	-	-	-	-	-
Dividends Paid	0	0	-106.25K	-436K	0	0	0	0	0	0
Share Repurchases	-	-	-	-	-	-	-	-	-	-
Other Financing	368.75K	166.77K	3.93M	12.83M	1.6M	973K	-1.16M	-1.71M	845K	-377K
Net Change in Cash	-	-	-	-	-	-	-	-	-	-
Free Cash Flow+	-6.39M	-5.58M	461.23K	1.85M	538K	1.88M	-13.22M	-18.87M	-18.88M	5.2M
FCF Margin %	-0.99%	-0.68%	0.04%	0.09%	0.02%	0.04%	-0.11%	-0.25%	-0.13%	0.06%
FCF Growth %	-0.7%	0.13%	1.08%	3.01%	-0.71%	2.5%	-8.02%	-0.43%	-0%	1.28%
FCF per Share	-0.52	-0.44	0.03	0.11	0.03	0.07	-0.34	-0.44	-0.43	0.11
FCF Conversion (FCF/Net Income)	1.18x	0.63x	-0.24x	0.72x	-0.73x	2.44x	0.54x	0.06x	0.19x	-0.42x
Interest Paid	0	0	0	0	0	0	0	0	0	0
Taxes Paid	0	0	0	0	0	0	0	0	0	0

Key Ratios

Metric	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024
Return on Equity (ROE)	-32.5%	-105.56%	-37.94%	12.27%	-2.63%	1.85%	-2.6%	-33.09%	-18.93%	-5.88%
Return on Invested Capital (ROIC)	-61.86%	-68.4%	-19.72%	34.5%	-1.3%	-2.45%	-9.36%	-1.08%	-14.51%	-1.7%
Gross Margin	59.15%	58.09%	61.2%	68.51%	67.64%	57.07%	31.68%	70.6%	32.63%	65.25%
Net Margin	-65.34%	-83.57%	-22.82%	16.54%	-6.05%	5.55%	-7.48%	-183.38%	-46.36%	-24.54%
Debt / Equity	-	0.90x	-	-	0.02x	0.05x	0.06x	0.12x	0.10x	0.09x
Interest Coverage	-	-15.24x	-2.32x	732.40x	-156.20x	-185.11x	-72.49x	-8.62x	-39.09x	-9.92x
FCF Conversion	1.18x	0.63x	-0.24x	0.72x	-0.73x	2.44x	0.54x	0.06x	0.19x	-0.42x
Revenue Growth	4.17%	27.57%	33.97%	79.11%	38.64%	75.69%	147.79%	-36.02%	87.92%	-42.59%

Revenue by Segment

	2019	2020	2021	2022	2023	2024
Product	-	-	-	-	117.69M	76.03M
Product Growth	-	-	-	-	-	-35.40%
Rental Revenue	-	-	14.8M	4.63M	8.03M	6.07M
Rental Revenue Growth	-	-	-	-68.68%	73.14%	-24.41%
Service	-	-	-	-	17.55M	160K
Service Growth	-	-	-	-	-	-99.09%
Service Revenue	-	4.55M	108K	210K	-	-
Service Revenue Growth	-	-	-97.63%	94.44%	-	-
Biopreservation Media	23.36M	-	-	-	-	-
Biopreservation Media Growth	-	-	-	-	-	-
Freezers and Accessories	2.14M	-	-	-	-	-
Freezers and Accessories Growth	-	-	-	-	-	-
Automated Thawing Products	1.18M	-	-	-	-	-
Automated Thawing Products Growth	-	-	-	-	-	-
Evo Shippers	692K	-	-	-	-	-
Evo Shippers Growth	-	-	-	-	-	-

Frequently Asked Questions

Growth & Financials

BioLife Solutions, Inc. (BLFS) reported $74.0M in revenue for fiscal year 2024. This represents a 2583% increase from $2.8M in 2011.

BioLife Solutions, Inc. (BLFS) saw revenue decline by 42.6% over the past year.

BioLife Solutions, Inc. (BLFS) reported a net loss of $3.2M for fiscal year 2024.

Dividend & Returns

BioLife Solutions, Inc. (BLFS) has a return on equity (ROE) of -5.9%. Negative ROE indicates the company is unprofitable.

BioLife Solutions, Inc. (BLFS) generated $10.6M in free cash flow for fiscal year 2024. Positive FCF indicates the company can fund dividends, buybacks, or reinvestment.